Brief: Travere Therapeutics Announces Full FDA Approval Of Filspari® (Sparsentan), The First And Only Approved Medicine For Fsgs
13/04/2026 23:24
April 13 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS ANNOUNCES FULL FDA APPROVAL OF FILSPARI® (SPARSENTAN), THE FIRST AND ONLY APPROVED MEDICINE FOR FSGS TRAVERE THERAPEUTICS INC - FILSPARI AVAILABLE ONLY THROUGH FILSPARI REMS PROGRAM TRAVERE THERAPEUTICS INC - FILSPARI INDICATION EXPANDS ADDRESSABLE POPULATION TO OVER 100,000 IN U.S. TRAVERE THERAPEUTICS:FILSPARI INDICATED TO REDUCE PROTEINURIA IN ADULTS & CHILDREN AGED 8 YEARS & OLDER WITH FSGS WHO DO NOT HAVE NEPHROTIC SYNDROME Source text: ID:nBw2g2HQ3a Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule